Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial.

Front Pharmacol · 2021 · PMC8443786 · PMID 34539392

Europe PMC DOI

hedged sentence

0.0541

closest p · 1.1× alpha

0.0541

boldest claim

The sentences

marginal significancep = 0.0541so close (0.05 < p ≤ 0.1)

Additionally, post hoc analysis showed that for moderate COVID-19 patients, favipiravir was associated with decreased auxiliary oxygen therapy or noninvasive mechanical ventilation rate with marginal significance ( p = 0.0541).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.